Phase I/II study of ipilimumab for patients with metastatic melanoma.

PubWeight™: 2.79‹?› | Rank: Top 1%

🔗 View Article (PMID 19018089)

Published in J Clin Oncol on November 17, 2008

Authors

Jeffrey S Weber1, Steven O'Day, Walter Urba, John Powderly, Geoff Nichol, Michael Yellin, Jolie Snively, Evan Hersh

Author Affiliations

1: University of Southern California/Norris Comprehensive Cancer Center, Los Angeles, CA, USA. jeffrey.weber@moffitt.org

Articles citing this

CTLA-4 blockade with ipilimumab: long-term follow-up of 177 patients with metastatic melanoma. Clin Cancer Res (2012) 4.56

Single-institution experience with ipilimumab in advanced melanoma patients in the compassionate use setting: lymphocyte count after 2 doses correlates with survival. Cancer (2010) 3.03

Integrated NY-ESO-1 antibody and CD8+ T-cell responses correlate with clinical benefit in advanced melanoma patients treated with ipilimumab. Proc Natl Acad Sci U S A (2011) 2.90

Depleting tumor-specific Tregs at a single site eradicates disseminated tumors. J Clin Invest (2013) 2.77

Preoperative CTLA-4 blockade: tolerability and immune monitoring in the setting of a presurgical clinical trial. Clin Cancer Res (2010) 2.73

Ipilimumab alone or in combination with radiotherapy in metastatic castration-resistant prostate cancer: results from an open-label, multicenter phase I/II study. Ann Oncol (2013) 2.35

Anti-PD-1 blockade and stereotactic radiation produce long-term survival in mice with intracranial gliomas. Int J Radiat Oncol Biol Phys (2013) 2.28

Cancer immunotherapy--revisited. Nat Rev Drug Discov (2011) 2.26

A phase II multicenter study of ipilimumab with or without dacarbazine in chemotherapy-naïve patients with advanced melanoma. Invest New Drugs (2010) 2.09

The price of tumor control: an analysis of rare side effects of anti-CTLA-4 therapy in metastatic melanoma from the ipilimumab network. PLoS One (2013) 2.01

Anti-CTLA-4 antibody therapy: immune monitoring during clinical development of a novel immunotherapy. Semin Oncol (2010) 1.98

Ipilimumab: an anti-CTLA-4 antibody for metastatic melanoma. Clin Cancer Res (2011) 1.97

Antibodies to watch in 2010. MAbs (2010) 1.90

Thyroid dysfunction from antineoplastic agents. J Natl Cancer Inst (2011) 1.86

Therapeutic cancer vaccines: are we there yet? Immunol Rev (2011) 1.86

Clinical effects of in situ photoimmunotherapy on late-stage melanoma patients: a preliminary study. Cancer Biol Ther (2010) 1.55

Phase I study of ipilimumab, an anti-CTLA-4 monoclonal antibody, in patients with relapsed and refractory B-cell non-Hodgkin lymphoma. Clin Cancer Res (2009) 1.48

Multicenter, phase II clinical trial of cancer vaccination for advanced esophageal cancer with three peptides derived from novel cancer-testis antigens. J Transl Med (2012) 1.47

Development of immuno-oncology drugs - from CTLA4 to PD1 to the next generations. Nat Rev Drug Discov (2016) 1.34

Immune-mediated adverse events associated with ipilimumab ctla-4 blockade therapy: the underlying mechanisms and clinical management. Scientifica (Cairo) (2013) 1.28

CTLA4 blockade increases Th17 cells in patients with metastatic melanoma. J Transl Med (2009) 1.28

Ipilimumab (yervoy) prolongs survival in advanced melanoma: serious side effects and a hefty price tag may limit its use. P T (2012) 1.19

Immune related adverse events associated with anti-CTLA-4 antibodies: systematic review and meta-analysis. BMC Med (2015) 1.18

Survival follow-up and ipilimumab retreatment of patients with advanced melanoma who received ipilimumab in prior phase II studies. Ann Oncol (2014) 1.11

Immunomodulatory therapy for melanoma: ipilimumab and beyond. Clin Dermatol (2013) 1.04

Hypophysitis induced by monoclonal antibodies to cytotoxic T lymphocyte antigen 4: challenges from a new cause of a rare disease. Oncologist (2012) 0.99

Predictive value of early 18F-FDG PET/CT studies for treatment response evaluation to ipilimumab in metastatic melanoma: preliminary results of an ongoing study. Eur J Nucl Med Mol Imaging (2014) 0.98

Cytotoxic T lymphocyte antigen-4 and immune checkpoint blockade. J Clin Invest (2015) 0.98

4-1BB Agonists: Multi-Potent Potentiators of Tumor Immunity. Front Oncol (2015) 0.97

CTLA-4 blockade following relapse of malignancy after allogeneic stem cell transplantation is associated with T cell activation but not with increased levels of T regulatory cells. Biol Blood Marrow Transplant (2010) 0.97

Pitfalls in the neuroimaging of glioblastoma in the era of antiangiogenic and immuno/targeted therapy - detecting illusive disease, defining response. Front Neurol (2015) 0.97

From clinical trials to clinical practice: therapeutic cancer vaccines for the treatment of prostate cancer. Expert Rev Vaccines (2011) 0.94

Radio-Immunotherapy-Induced Immunogenic Cancer Cells as Basis for Induction of Systemic Anti-Tumor Immune Responses - Pre-Clinical Evidence and Ongoing Clinical Applications. Front Immunol (2015) 0.92

Immunologic response to xenogeneic gp100 DNA in melanoma patients: comparison of particle-mediated epidermal delivery with intramuscular injection. Clin Cancer Res (2010) 0.90

Prognostic impact of tumour-infiltrating immune cells on biliary tract cancer. Br J Cancer (2013) 0.90

Profile of ipilimumab and its role in the treatment of metastatic melanoma. Drug Des Devel Ther (2011) 0.90

IgE-based immunotherapy of cancer: challenges and chances. Allergy (2013) 0.89

Melanoma in pediatric, adolescent, and young adult patients. Semin Oncol (2009) 0.89

Ipilimumab and cancer immunotherapy: a new hope for advanced stage melanoma. Yale J Biol Med (2011) 0.88

Baseline circulating IL-17 predicts toxicity while TGF-β1 and IL-10 are prognostic of relapse in ipilimumab neoadjuvant therapy of melanoma. J Immunother Cancer (2015) 0.88

Phase I study of ipilimumab in phased combination with paclitaxel and carboplatin in Japanese patients with non-small-cell lung cancer. Invest New Drugs (2015) 0.88

Immune checkpoint inhibitors: therapeutic advances in melanoma. Ann Transl Med (2015) 0.87

Humanized mice as a model for aberrant responses in human T cell immunotherapy. J Immunol (2014) 0.86

Beyond cancer vaccines: a reason for future optimism with immunomodulatory therapy. Cancer J (2011) 0.86

Use of ipilimumab in the treatment of melanoma. Clin Pharmacol (2013) 0.86

Melanoma patients in a phase I clinic: molecular aberrations, targeted therapy and outcomes. Ann Oncol (2013) 0.85

Anti-cytotoxic T lymphocyte antigen-4 antibodies in melanoma. Clin Cosmet Investig Dermatol (2013) 0.85

Targeting immune checkpoints in unresectable metastatic cutaneous melanoma: a systematic review and meta-analysis of anti-CTLA-4 and anti-PD-1 agents trials. Cancer Med (2016) 0.84

Demystifying immunotherapy in prostate cancer: understanding current and future treatment strategies. Cancer J (2013) 0.84

Immunotherapy and therapeutic vaccines in prostate cancer: an update on current strategies and clinical implications. Asian J Androl (2014) 0.84

Cancer immunotherapy - immune checkpoint blockade and associated endocrinopathies. Nat Rev Endocrinol (2017) 0.82

Advanced malignant melanoma: immunologic and multimodal therapeutic strategies. J Oncol (2010) 0.82

Antibody therapies for melanoma: new and emerging opportunities to activate immunity (Review). Oncol Rep (2014) 0.82

Ipilimumab and whole brain radiation therapy for melanoma brain metastases. J Neurooncol (2014) 0.82

Oncolytic virotherapy as emerging immunotherapeutic modality: potential of parvovirus h-1. Front Oncol (2014) 0.82

Apoptosis-regulated low-avidity cancer-specific CD8(+) T cells can be rescued to eliminate HER2/neu-expressing tumors by costimulatory agonists in tolerized mice. Cancer Immunol Res (2014) 0.81

Evolving Concepts: Immunity in Oncology from Targets to Treatments. J Oncol (2015) 0.81

Recent advances relating to the clinical application of naked monoclonal antibodies in solid tumors. Mol Med (2009) 0.81

Integrating costimulatory agonists to optimize immune-based cancer therapies. Immunotherapy (2009) 0.81

Model-based clinical pharmacology profiling of ipilimumab in patients with advanced melanoma. Br J Clin Pharmacol (2014) 0.81

Blockade of cytotoxic T-lymphocyte antigen-4 as a new therapeutic approach for advanced melanoma. Expert Opin Pharmacother (2011) 0.80

Modulation of CTLA-4 and GITR for cancer immunotherapy. Curr Top Microbiol Immunol (2011) 0.80

Ipilimumab, a promising immunotherapy with increased overall survival in metastatic melanoma? Dermatol Res Pract (2011) 0.80

Regulatory T-cells in chronic lymphocytic leukemia: actor or innocent bystander? Am J Blood Res (2013) 0.80

Phase I Clinical Trial of Ipilimumab in Pediatric Patients with Advanced Solid Tumors. Clin Cancer Res (2015) 0.80

Fractal and multifractal analysis of PET/CT images of metastatic melanoma before and after treatment with ipilimumab. EJNMMI Res (2016) 0.79

Next generation therapies change the landscape in melanoma. F1000 Med Rep (2011) 0.79

Ipilimumab pharmacotherapy in patients with metastatic melanoma. Clin Med Insights Oncol (2012) 0.78

Major histocompatibility complex class I expression impacts on patient survival and type and density of immune cells in biliary tract cancer. Br J Cancer (2015) 0.78

The evaluation of immunotherapy and chemotherapy treatment on melanoma: a network meta-analysis. Oncotarget (2016) 0.77

Crosstalk in skin: melanocytes, keratinocytes, stem cells, and melanoma. J Cell Commun Signal (2016) 0.76

The monoclonal antibody to cytotoxic T lymphocyte antigen 4, ipilimumab, in the treatment of melanoma. Cancer Manag Res (2012) 0.76

Prioritization schema for immunotherapy clinical trials in glioblastoma. Oncoimmunology (2016) 0.76

Safety of Infusing Ipilimumab Over 30 Minutes. J Clin Oncol (2015) 0.76

Antitumor vaccination of prostate cancer patients elicits PD-1/PD-L1 regulated antigen-specific immune responses. Oncoimmunology (2016) 0.76

Improved time to disease progression in the brain in patients with melanoma brain metastases treated with concurrent delivery of radiosurgery and ipilimumab. Oncoimmunology (2017) 0.75

Ipilimumab (Anti-Ctla-4 Mab) in the treatment of metastatic melanoma: Effectiveness and toxicity management. Hum Vaccin Immunother (2016) 0.75

Targeting precision medicine toxicity: recent developments. Ther Adv Drug Saf (2015) 0.75

Diversification of Antitumour Immunity in a Patient with Metastatic Melanoma Treated with Ipilimumab and an IDO-Silenced Dendritic Cell Vaccine. Case Rep Med (2016) 0.75

[(18)F]Fluorodeoxyglucose Positron Emission Tomography Reveals a Complete Remission of Refractory Metastatic Melanoma after Therapy with Ipilimumab. Indian J Nucl Med (2017) 0.75

Thermal Ablative Therapies and Immune Checkpoint Modulation: Can Locoregional Approaches Effect a Systemic Response? Gastroenterol Res Pract (2016) 0.75

Radiotherapy and immunotherapy: a beneficial liaison? Nat Rev Clin Oncol (2017) 0.75

Nuclear Molecular Imaging Strategies in Immune Checkpoint Inhibitor Therapy. Diagnostics (Basel) (2017) 0.75

Current status of chimeric antigen receptor engineered T cell-based and immune checkpoint blockade-based cancer immunotherapies. Cancer Immunol Immunother (2017) 0.75

Ipilimumab: from preclinical development to future clinical perspectives in melanoma. Future Oncol (2016) 0.75

Metastatic melanoma imaging using a novel Tc-99m-labeled lactam-cyclized alpha-MSH peptide. Bioorg Med Chem Lett (2017) 0.75

Fixed Dosing of Monoclonal Antibodies in Oncology. Oncologist (2017) 0.75

NLRC5/CITA: A Key Player in Cancer Immune Surveillance. Trends Cancer (2017) 0.75

A Pilot Study of Post-Operative Adjuvant Vaccine for Advanced Gastric Cancer. Yonago Acta Med (2017) 0.75

Profile of pembrolizumab in the treatment of head and neck squamous cell carcinoma: design development and place in therapy. Drug Des Devel Ther (2017) 0.75

Articles by these authors

Ipilimumab plus dacarbazine for previously untreated metastatic melanoma. N Engl J Med (2011) 26.90

Guidelines for the evaluation of immune therapy activity in solid tumors: immune-related response criteria. Clin Cancer Res (2009) 24.11

Autoimmunity correlates with tumor regression in patients with metastatic melanoma treated with anti-cytotoxic T-lymphocyte antigen-4. J Clin Oncol (2005) 9.72

Gene editing of CCR5 in autologous CD4 T cells of persons infected with HIV. N Engl J Med (2014) 7.64

Enterocolitis in patients with cancer after antibody blockade of cytotoxic T-lymphocyte-associated antigen 4. J Clin Oncol (2006) 7.40

Results of a phase III, randomized, placebo-controlled study of sorafenib in combination with carboplatin and paclitaxel as second-line treatment in patients with unresectable stage III or stage IV melanoma. J Clin Oncol (2009) 6.44

Prognostic factors related to clinical response in patients with metastatic melanoma treated by CTL-associated antigen-4 blockade. Clin Cancer Res (2007) 5.51

Tumor regression and autoimmunity in patients treated with cytotoxic T lymphocyte-associated antigen 4 blockade and interleukin 2: a phase I/II study. Ann Surg Oncol (2005) 5.36

Autoimmunity in a phase I trial of a fully human anti-cytotoxic T-lymphocyte antigen-4 monoclonal antibody with multiple melanoma peptides and Montanide ISA 51 for patients with resected stages III and IV melanoma. J Clin Oncol (2004) 4.09

Double-blind randomized phase II study of the combination of sorafenib and dacarbazine in patients with advanced melanoma: a report from the 11715 Study Group. J Clin Oncol (2008) 3.58

A clinical development paradigm for cancer vaccines and related biologics. J Immunother (2007) 2.97

Phase I and pharmacokinetics trial of ABI-007, a novel nanoparticle formulation of paclitaxel in patients with advanced nonhematologic malignancies. J Clin Oncol (2005) 2.53

Results from a randomized phase III study comparing combined treatment with histamine dihydrochloride plus interleukin-2 versus interleukin-2 alone in patients with metastatic melanoma. J Clin Oncol (2002) 2.26

A phase II multicenter study of ipilimumab with or without dacarbazine in chemotherapy-naïve patients with advanced melanoma. Invest New Drugs (2010) 2.09

Tumor genetic analyses of patients with metastatic melanoma treated with the BRAF inhibitor dabrafenib (GSK2118436). Clin Cancer Res (2013) 1.55

Extended dose ipilimumab with a peptide vaccine: immune correlates associated with clinical benefit in patients with resected high-risk stage IIIc/IV melanoma. Clin Cancer Res (2010) 1.54

The Society for Immunotherapy of Cancer consensus statement on tumour immunotherapy for the treatment of cutaneous melanoma. Nat Rev Clin Oncol (2013) 1.46

Phase I/II study of an anti-CD30 monoclonal antibody (MDX-060) in Hodgkin's lymphoma and anaplastic large-cell lymphoma. J Clin Oncol (2007) 1.38

Tumor immunotherapy: preclinical and clinical activity of anti-CTLA4 antibodies. Curr Opin Investig Drugs (2005) 1.34

A phase II, randomized, double-blind, placebo-controlled study evaluating the efficacy and safety of MDX-1100, a fully human anti-CXCL10 monoclonal antibody, in combination with methotrexate in patients with rheumatoid arthritis. Arthritis Rheum (2011) 1.32

Induction of antigen-specific immunity with a vaccine targeting NY-ESO-1 to the dendritic cell receptor DEC-205. Sci Transl Med (2014) 1.30

Efficacy and safety of retreatment with ipilimumab in patients with pretreated advanced melanoma who progressed after initially achieving disease control. Clin Cancer Res (2013) 1.23

Survival and pattern of failure in brain metastasis treated with stereotactic gamma knife radiosurgery. J Neurosurg (2002) 1.22

Serial monitoring of circulating tumor cells predicts outcome of induction biochemotherapy plus maintenance biotherapy for metastatic melanoma. Clin Cancer Res (2010) 1.19

Randomized phase I pharmacokinetic study of ipilimumab with or without one of two different chemotherapy regimens in patients with untreated advanced melanoma. Cancer Immun (2013) 1.17

Phase I study utilizing a novel antigen-presenting cell-targeted vaccine with Toll-like receptor stimulation to induce immunity to self-antigens in cancer patients. Clin Cancer Res (2011) 1.15

Phase 1 trial of intranodal injection of a Melan-A/MART-1 DNA plasmid vaccine in patients with stage IV melanoma. J Immunother (2008) 1.11

Ipilimumab: unleashing the power of the immune system through CTLA-4 blockade. Semin Oncol (2010) 1.11

Phase I study of intranodal delivery of a plasmid DNA vaccine for patients with Stage IV melanoma. Cancer (2003) 1.08

Metastatic melanoma to the brain: prognostic factors after gamma knife radiosurgery. Int J Radiat Oncol Biol Phys (2002) 1.07

Phase I trial of imexon in patients with advanced malignancy. J Clin Oncol (2007) 1.07

A randomized phase 2 study of etaracizumab, a monoclonal antibody against integrin alpha(v)beta(3), + or - dacarbazine in patients with stage IV metastatic melanoma. Cancer (2010) 1.06

Anti-IP-10 antibody (BMS-936557) for ulcerative colitis: a phase II randomised study. Gut (2013) 1.05

Phase I pilot clinical trial of human IgM monoclonal antibody to ganglioside GM3 in patients with metastatic melanoma. Cancer Immunol Immunother (2003) 0.98

Suppression of murine cardiac allograft arteriopathy by long-term blockade of CD40-CD154 interactions. Circulation (2002) 0.98

Randomized phase 2/3 trial of CpG oligodeoxynucleotide PF-3512676 alone or with dacarbazine for patients with unresectable stage III and IV melanoma. Cancer (2009) 0.97

Prognostic factors in metastatic melanoma patients treated with biochemotherapy and maintenance immunotherapy. Oncologist (2009) 0.94

The role of the CTLA4 blockade in the treatment of malignant melanoma. Cancer Invest (2007) 0.93

A phase I trial of imexon, a pro-oxidant, in combination with docetaxel for the treatment of patients with advanced breast, non-small cell lung and prostate cancer. Invest New Drugs (2009) 0.92

Preclinical antitumor activity, pharmacokinetics and pharmacodynamics of imexon in mice. Anticancer Drugs (2006) 0.89

A phase I study of the dolastatin-15 analogue tasidotin (ILX651) administered intravenously daily for 5 consecutive days every 3 weeks in patients with advanced solid tumors. Clin Cancer Res (2005) 0.88

A phase I trial of SD-9427 (progenipoietin) with a multipeptide vaccine for resected metastatic melanoma. Clin Cancer Res (2003) 0.88

Pharmacokinetics of histamine dihydrochloride in healthy volunteers and cancer patients: implications for combined immunotherapy with interleukin-2. J Clin Pharmacol (2002) 0.85

Low-dose outpatient chemobiotherapy with temozolomide, granulocyte-macrophage colony stimulating factor, interferon-alpha2b, and recombinant interleukin-2 for the treatment of metastatic melanoma. J Clin Oncol (2005) 0.85

Metastatic melanoma to the liver: a contemporary and comprehensive review of surgical, systemic, and regional therapeutic options. Cancer (2013) 0.84

A phase II open-label trial of apomine (SR-45023A) in patients with refractory melanoma. Invest New Drugs (2006) 0.83

Phase II study of nab-paclitaxel and bevacizumab as first-line therapy for patients with unresectable stage III and IV melanoma. Am J Clin Oncol (2015) 0.83

Radiation and immunotherapy: Renewed allies in the war on cancer. Oncoimmunology (2012) 0.83

A phase 1-2 study of imexon plus dacarbazine in patients with unresectable metastatic melanoma. Cancer (2010) 0.83

Case 3. Positron emission tomography-computed tomography diagnosis of metastatic melanoma with intussusception. J Clin Oncol (2004) 0.82

A phase II study of biochemotherapy for advanced melanoma incorporating temozolomide, decrescendo interleukin-2 and GM-CSF. Cancer Invest (2005) 0.80

Metabolic response by FDG-PET to imatinib correlates with exon 11 KIT mutation and predicts outcome in patients with mucosal melanoma. Cancer Imaging (2014) 0.78

Results of a multicenter, randomized, double-blind, dose-evaluating phase 2/3 study of lenalidomide in the treatment of metastatic malignant melanoma. Cancer (2009) 0.77

Meeting report from the Third Global Workshop on Melanoma. Pigment Cell Melanoma Res (2010) 0.76

Targeting and amplification of immune killing of tumor cells by pro-Smac. Int J Cancer (2004) 0.75